Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 1/Phase 2

ARTEMIDE-01

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

ChannelFound
X threads8

The trial

ClinicalTrials.gov
Official title
Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Phase
Phase 1/Phase 2
Status
Active, not recruiting
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
AZD2936
Arms
  • Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced Non-small Cell Lung Cancer (NSCLC) · Experimental
  • Dose Expansion Part B: CPI experienced NSCLC · Experimental
  • Dose Expansion Part C: CPI Naive NSCLC · Experimental
  • Dose Expansion Part D: CPI Naive NSCLC · Experimental
  • Dose Expansion Part E: treatment Naive Squamous NSCLC · Experimental
Enrollment
212
Primary outcomes
  • Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
  • Rate of rilvegostomig discontinuation due to toxicity
  • Objective Response Rate (ORR)
Sponsor
AstraZeneca
Start
Sep 14, 2021
Primary completion
Aug 28, 2026 (estimated)
Results posted
No
Registry record
NCT04995523 · updated Jul 14, 2026